Advertisement
Canada markets close in 5 minutes

  • S&P/TSX

    21,881.29
    -130.43 (-0.59%)
     

  • S&P 500

    5,075.47
    +4.92 (+0.10%)
     

  • DOW

    38,504.15
    +0.46 (+0.00%)
     

  • CAD/USD

    0.7300
    -0.0020 (-0.28%)
     

  • CRUDE OIL

    82.91
    -0.45 (-0.54%)
     

  • Bitcoin CAD

    88,081.87
    -2,995.48 (-3.29%)
     

  • CMC Crypto 200

    1,391.11
    -32.99 (-2.32%)
     

  • GOLD FUTURES

    2,332.30
    -9.80 (-0.42%)
     

  • RUSSELL 2000

    1,992.68
    -9.96 (-0.50%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ

    15,722.76
    +26.12 (+0.17%)
     

  • VOLATILITY

    15.73
    +0.04 (+0.25%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

  • CAD/EUR

    0.6818
    -0.0018 (-0.26%)
     
MARKETS LIVE BLOG:

STOCKS SHED GAINS, TESLA SURGES DAY AFTER EARNINGS

Tesla shares jump after EV maker vows to speed up launch of more affordable models

Stocks in play: Aptose Biosciences Inc.

Baystreet.ca
Updated
Announced an exclusive global license agreement that provides OHM Oncology (“OHM”) with the rights for ...

Announced an exclusive global license agreement that provides OHM Oncology (“OHM”) with the rights for the development, manufacture and commercialization of APL-581, as well as related molecules from Aptose’s dual bromodomain and extra-terminal domain motif (BET) protein and kinase inhibitor program. Aptose will retain reacquisition rights to certain molecules, while OHM will have the rights to develop and sublicense all other molecules. Aptose Biosciences Inc.